TARS Tarsus Pharmaceuticals

Tarsus to Participate in Upcoming Investor Conferences

Tarsus to Participate in Upcoming Investor Conferences

IRVINE, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management will participate in fireside chats at two upcoming investor conferences:

  • The Guggenheim SMID Cap Biotech Conference on Thursday, February 6th, at 6:00 a.m. PT / 9:00 a.m. ET
  • The Oppenheimer 35th Annual Healthcare Life Sciences Conference on Wednesday, February 12th, at 7:00 a.m. PT / 10:00 a.m. ET

A live webcast and additional information can be accessed on the events section of the Tarsus . The replay will be available on the Tarsus website within 48 hours and will be archived for a limited time.

About Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care and infectious disease prevention. XDEMVY® (lotilaner ophthalmic solution, 0.25%) is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-04 for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease.

Media Contact:

Adrienne Kemp

Sr. Director, Corporate Communications

(949) 922-0801

Investor Contact:

David Nakasone

Head of Investor Relations

(949) 620-3223



EN
30/01/2025

Underlying

TARSTarsus Pharmaceuticals

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Tarsus Pharmaceuticals

 PRESS RELEASE
Free
TARS Tarsus Pharmace...

Tarsus to Participate in Upcoming Investor Conferences

Tarsus to Participate in Upcoming Investor Conferences IRVINE, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management will participate in fireside chats at two upcoming investor conferences: The Guggenheim SMID Cap Biotech Conference on Thursday, February 6th, at 6:00 a.m. PT / 9:00 a.m. ETThe Oppenheimer 35th Annual Healthcare Life Sciences Conference on Wednesday, February 12th, at 7:00 a.m. PT / 10:00 a.m. ET A live webcast and additional information can be accessed on the events section of the Tarsus . The replay will b...

January 30, 2025 1 EN
 PRESS RELEASE
Free
TARS Tarsus Pharmace...

Tarsus Provides 2025 Update: Accelerating the Launch of XDEMVY® and Es...

Tarsus Provides 2025 Update: Accelerating the Launch of XDEMVY® and Establishing Ocular Rosacea as the Next Category-Creating Opportunity in Eye Care Advancing TP-04 (lotilaner ophthalmic gel) for the potential treatment of Ocular Rosacea, another large, underserved eye disease with no FDA-approved therapy; Initiation of Phase 2 study planned for 2H 2025 Management to host webcast on Tuesday, January 14, 2025, at 8:00 a.m. P.T. / 11:00 a.m. E.T. IRVINE, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today provided an update on the Company’s key pri...

January 13, 2025 1 EN
Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke
EUR 48.26
ANET Arista Networks...
WBA Walgreens Boots... ... (+48)

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

ANET ARISTA NETWORKS INC.
WBA WALGREENS BOOTS ALLIANCE INC
TSLA TESLA INC
TGTX TG THERAPEUTICS INC.
NVCR NOVOCURE LTD.
MXL MAXLINEAR INC
DAKT DAKTRONICS INC.
CIEN CIENA CORPORATION
JOUT JOHNSON OUTDOORS INC. CLASS A
AAOI APPLIED OPTOELECTRONICS INC.
GIII G-III APPAREL GROUP LTD.
FLXS FLEXSTEEL INDUSTRIES INC.
KINS KINGSTONE COS. INC.
SENEA SENECA FOODS CORP. CL A
RH RH
REVG REV GROUP INC.
STRT STRATTEC SECURITY CORP.
RIOT RIOT BLOCKCHAIN
AVGO BROADCOM INC.
ATOM ATOMERA
TARS TARSUS PHARMACEUTICALS
UPST UPSTART HOLDINGS
NOTV INOTIV INC
MRVL MARVELL TECHNOLOGY INC
QUBT QUANTUM COMPUTING INC
REE REE AUTOMOTIVE LTD
TASK TASKUS INC
VSCO VICTORIA'S SECRET & CO
ACHR ARCHER AVIATION INC
FINW FINWISE BANCORP
STVN STEVANATO GRP SPA
CRDO CREDO TECHNOLOGY GRP HLDG LTD
RGTI RIGETTI COMPUTING INC
OPFI OPPFI INC
COHR COHERENT CORP
ATGL ALPHA TECHNOLOGY GROUP LTD
BTSG BRIGHTSPRING HEALTH SERVICES INC.
AS AMER SPORTS INC.
ALAB ASTERA LABS INC
AIRJ MONTANA TECHNOLOGIES CORP
BKKT BAKKT HOLDINGS INC.
GRALV GRAIL INC.
RDDT REDDIT INC
SERV SERVE ROBOTICS INC
CDTX CIDARA THERAPEUTICS INC.
AMPL AMPLITUDE INC
LGCY LEGACY EDUCATION INC.
CCB CHASE CAPITAL VIII CAP SEC H 8.25%
12/16/24 December 16, 2024 1 EN
 PRESS RELEASE
Free
TARS Tarsus Pharmace...

Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results a...

Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements Generated $48.1 million in XDEMVY® net product sales driven by more than 41,400 bottles delivered to patients in the third quarter Strengthened payer coverage highlighted by securing the two remaining large Medicare contracts; broad commercial and Medicare coverage now extends to more than 80% of covered lives New XDEMVY data demonstrated statistically significant and clinically meaningful improvements from baseline across objective measures of Meibomian Gland Disease and important patien...

November 13, 2024 1 EN
 PRESS RELEASE
Free
TARS Tarsus Pharmace...

Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors

Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors Humana CMO brings more than two decades of experience driving innovative, value-based initiatives designed to improve patient outcomes IRVINE, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced the appointment of Katherine H. (Kate) Goodrich, M.D., MHS, Chief Medical Officer of Humana Inc., to its Board of Directors. Dr. G...

November 13, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch